Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe”

On September 15-17, 2022, the EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was successfully held at the Occidental Praha hotel in Prague, Czechia.

Read more

EuroBloodNet aims for better care for patients with rare blood disorders

ERNs is an initiative of the European Commission and consist of networks of healthcare providers and centers of excellence in Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

 

Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.

Read more